Nuvalent (NUVL) Other Non-Current Liabilities (2024 - 2025)

Nuvalent (NUVL) reported Other Non-Current Liabilities of $35000.0 for Q4 2025, down 75.0% quarter-over-quarter from $140000.0 in Q3 2025.

Nuvalent (NUVL) Other Non-Current Liabilities (2024 - 2025) Analysis & Trends

Nuvalent has reported Other Non-Current Liabilities for 2 years, with the latest figure at $35000.0 in Q4 2025.

For the quarter ending Q4 2025, Other Non-Current Liabilities changed N/A year-over-year to $35000.0; the trailing twelve-month figure through Dec 2025 stood at $35000.0 (changed N/A YoY), and the FY2025 full-year result was $35000.0, changed N/A from the prior year.
Other Non-Current Liabilities for Q4 2025 stood at $35000.0, down from $140000.0 in the prior quarter.
The five-year high for Other Non-Current Liabilities was $16.6 million in Q3 2024, with the low at $35000.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn
9	Abivax	91.71 Bn	91.71 Bn	-
10	Nuvalent	9.70 Bn	9.70 Bn	-

Download Data